key: cord-0687721-wfg6sftw
authors: Okoye, Ginette A.; Kamara, Haja I.; Strobeck, Michelle; Mellman, Thomas Alan; Kwagyan, John; Sullivan, Ava; Byrd, Angel S.; Shokrani, Babak; Mighty, Hugh E.
title: Diagnostic accuracy of a rapid diagnostic test for the early detection of COVID-19
date: 2021-10-28
journal: J Clin Virol
DOI: 10.1016/j.jcv.2021.105023
sha: 820e52ccd402bf2773ab6aee8c4d19f2cabce9e3
doc_id: 687721
cord_uid: wfg6sftw

OBJECTIVES: This study was undertaken to evaluate the diagnostic performance of the BinaxNOW COVID-19 Ag Card rapid antigen assay (Abbott; Chicago, IL, USA) in the detection of COVID-19 infection compared to the reference standard of PCR testing. METHODS: We evaluated the BinaxNOW COVID-19 Ag Card rapid antigen assay relative to a standard reference PCR test. We tested 3810 nasal swabs from symptomatic and asymptomatic adults undergoing surveillance COVID-19 testing at Howard University using one swab for each nostril. One swab was tested using the rapid antigen assay and the other using the PCR test. RESULTS: The sensitivity of the BinaxNOW COVID-19 Ag Card rapid antigen assay was 91.84% (95% confidence interval (CI): 80.40-97.73%) and the specificity was 99.95% (95% CI: 99.81-99.99%). The range of Ct values for the N gene was 10.74-34.90 (M=26.88, SD=4.86). Fourteen (28.6%) samples had an N gene Ct value > 30. The average N gene Ct value for rapid test negative (i.e. false negative) samples as 31.92. CONCLUSIONS: The sensitivity of the test in our symptomatic and asymptomatic cohort was lower than the manufacturer's reported sensitivity in a symptomatic cohort (97.1%). Despite their relatively lower sensitivity (especially in asymptomatic individuals), rapid tests have undeniable benefits (i.e., ease of use and rapid results) that make them a helpful tool in the control of the SARS-CoV-2 pandemic. Given the diagnostic accuracy of these tests as evidenced by this study, rapid tests can be thoughtfully employed in situations where swift results are critical.

Diagnostic accuracy of a rapid diagnostic test for the early detection of COVID-19.

This study was undertaken to evaluate the diagnostic performance of the BinaxNOW COVID-19 Ag Card rapid antigen assay (Abbott; Chicago, IL, USA) in the detection of COVID-19 infection compared to the reference standard of PCR testing.

We evaluated the BinaxNOW COVID-19 Ag Card rapid antigen assay relative to a standard reference PCR test. We tested 3810 nasal swabs from symptomatic and asymptomatic adults undergoing surveillance COVID-19 testing at Howard University using one swab for each nostril. One swab was tested using the rapid antigen assay and the other using the PCR test.

The sensitivity of the BinaxNOW COVID-19 Ag Card rapid antigen assay was 91. 84% 

The sensitivity of the test in our symptomatic and asymptomatic cohort was lower than the manufacturer's reported sensitivity in a symptomatic cohort (97.1%). Despite their relatively lower sensitivity (especially in asymptomatic individuals), rapid tests have undeniable benefits (i.e., ease of use and rapid results) that make them a helpful tool in the control of the SARS-CoV-2 pandemic. Given the diagnostic accuracy of these tests as evidenced by this study, rapid tests can be thoughtfully employed in situations where swift results are critical.

Keywords: Coronavirus; COVID-19; RT-PCR; rapid testing; diagnostic accuracy Background Early diagnosis of COVID-19 is critical to reducing person-to-person transmission.

Laboratory diagnosis through polymerase chain reaction (PCR) testing, considered the standard reference, may take up to 24 hours for the results to be confirmed with additional time for transport, whereas diagnosis through rapid antigen testing can take as few as 15 minutes and be done at the point of care. Rapid and easy-to-perform diagnostic tests therefore allow for earlier initiation of isolation and more effective contact tracing, thereby decreasing transmission of COVID-19.

As rapid testing becomes more available, characteristics of the diagnostic performance of these tests relative to the standard reference, including sensitivity, specificity, positive and negative predictive values are critical to their impact on public health. False negative COVID-19 test results in particular pose a challenge to public health efforts to reduce the spread of the virus. Individuals with false negative results, believing they do not have COVID-19, may stop practicing measures to reduce the spread of the virus, including maskwearing, social distancing, and avoiding large gatherings [1] . False negative results also limit health professionals' ability to conduct contact tracing and testing of exposed individuals.

Abbott, the producers of the BinaxNOW COVID-19 Ag Card rapid antigen assay, evaluated the clinical performance of their assay through a multi-site prospective study including 10 sites in the United States [2] . The analysis of 460 nasal swabs from symptomatic patients with suspected COVID-19 infection revealed a sensitivity of 97.1% and a specificity of 98.5% when compared to a real time Polymerase Chain Reaction (RT-PCR) [3] .

This study was undertaken to evaluate the diagnostic performance of a BinaxNOW COVID-19 Ag Card rapid antigen assay (Abbott; Chicago, IL, USA) in the detection of COVID-19 infection in relation to the reference standard of PCR testing in asymptomatic and symptomatic adults undergoing COVID-19 testing at Howard University.

In this single-center study, the results of 3810 anterior nasal swab samples were analyzed.

The samples were collected by a healthcare provider from September to December 2020 from adults undergoing periodic employer-mandated COVID-19 surveillance testing at Howard University. Information on the presence or absence of COVID19 symptoms was not collected in all tested individuals. Two swabs were used to collect samples, one for each nostril. One was used for the BinaxNOW COVID-19 Ag Card rapid antigen assay which was performed at the point of care, and the second swab was analyzed using the Applied Biosystems TaqPath COVID-19 RT-PCR kit (Thermo Fisher Scientific Inc.; Waltham, MA, USA) in an institutional reference laboratory. In the event that the results from each nostril did not match, the result provided by the PCR test was accepted, as it is the reference standard test. The primary outcomes were sensitivity, specificity and overall (global) diagnostic accuracy of the rapid antigen assay measured against the PCR testing. Secondary outcomes were negative predictive value (NPV) and positive predictive value (PPV).

The BinaxNOW COVID-19 Ag Card is an assay that uses antibodies to detect SARS-CoV-2 proteins from nasal swab specimens. The samples were taken from the patient using a sterile nasal swab which were then inserted into a cardboard test card along with 6 drops of an extraction reagent. When the card is closed, the sample specimen comes into contact with the test strip and sits for 15 minutes. After that time, the provider interpreted the test visually based on the presence of pink/purple lines on the test card. Results were read promptly at 15 minutes, as they are considered invalid after 30 minutes [2] .

The reference standard PCR test for detection of COVID-19 qualitatively detects nucleic acid from SARS-CoV-2. The sample was taken from the patient using a sterile nasal swab, which was then sent to an institutional reference laboratory for PCR testing. RNA was then Table 2) . The average N gene Ct value for rapid test negative (i.e. false negative) samples as 31.92.

Testing the diagnostic accuracy of rapid antigen assays for the detection of COVID-19 has widespread implications for our efforts to curb the spread of the SARS-CoV-2 virus. Rapid tests are practical and have become increasingly popular as a strategy for hosting large scale events and reopening schools [4] . Previous studies have found rapid tests to be inferior to the gold-standard PCR test for the detection of COVID-19, citing low sensitivity as the major limitation. For example, in real-world studies, the sensitivity of the PanBio TM rapid antigen test (also manufactured by Abbott Laboratories), ranges from 74.4%-86.8 % [5, 6] .

The results of this study of the BinaxNOW rapid antigen test in symptomatic and asymptomatic individuals demonstrate a lower sensitivity (91.84%) than that reported by the manufacturer (97.1%) [2] . However, it is important to note that the sensitivity of this test is higher in symptomatic individuals [2, 7] . A limitation of our study is the lack of complete data on the symptomatic vs. asymptomatic status of our cohort. However, a recent study of the same rapid test in a cohort of symptomatic and asymptomatic individuals reported similar results (sensitivity 93.3% and specificity 99.9%) [8] , suggesting that our cohort also included both symptomatic and asymptomatic individuals.

The relatively lower sensitivity of rapid tests must be weighed against their benefits, (i.e., room temperature storage, easy to use, and quick turnaround time for results). Though imperfect, rapid tests can be thoughtfully employed to screen symptomatic and asymptomatic individuals in situations where swift results are critical.

COVID-19 testing: the threat of false-negative results

Upping the ante on COVID-19 antigen testing

Buyer beware: inflated claims of sensitivity for rapid COVID-19 tests

Panbio™ rapid antigen test for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary health care

Evaluation of the accuracy and ease-of-use of Abbott PanBio-A WHO emergency use listed, rapid, antigen-detecting point-of-care diagnostic test for SARS-CoV-2. PLoS One

Performance and implementation evaluation of the Abbott BinaxNOW rapid antigen test in a high-throughput drive-through community testing site in Massachusetts

Performance characteristics of a rapid SARS-CoV-2 antigen detection assay at a public plaza testing site in San Francisco

The authors have no conflicts of interest to declare.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: